Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

ViaCyte

company

About

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes.

  • 101 - 250

Details

Last Funding Type
Series D
Last Funding Money Raised
$80M
Industries
Biotechnology,Diabetes,Health Care,Medical,Therapeutics
Founded date
Jan 1, 1999
Number Of Employee
101 - 250
Operating Status
Active

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$110M
ViaCyte has raised a total of $110M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2018 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 29, 2018 Series D $80M 1 Detail
May 22, 2017 Series Unknown $10M 1 Detail
May 3, 2006 Series Unknown $20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
ViaCyte is funded by 3 investors. TPG and Asset Management Partners are the most recent investors.
Investor Name Lead Investor Funding Round
TPG Series D
Asset Management Partners Series Unknown
Headland Ventures Series Unknown